De-escalation of therapy for patients with ductal carcinoma in situ (DCIS) was surveyed in 4 questions. Almost all panellists (98%) agreed that screening-detected, small DCIS with favourable biological features (e.g. G1-2, or other low risk features) has a better prognosis and therefore may require less intensive treatment. In line with this, 84% of the panellists found it a reasonable option to omit radiotherapy for patients with DCIS with favourable features and a clear tumour-free surgical margin (≥ 5 mm). Only a small majority of the panellists (56%) found it a reasonable option to omit endocrine therapy in these patients, while 66% of the panellists found it a reasonable option to omit both radiotherapy and endocrine therapy.
« Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy Next Article
Radioguided surgery is the future? »
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.